Male Hypoactive Sexual Desire Disorder
HSDD in men, low desire as a diagnosis distinct from ED
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved drug for male HSDD specifically
Reference only. Not medical advice.
What can go wrong
The risk is mislabeling: treating a desire disorder as ED (with PDE5 inhibitors that do nothing for desire), or assuming all low desire is low testosterone and prescribing hormones inappropriately. Proper diagnosis requires the distress and duration criteria plus evaluation of mood, medications, relationship factors, and endocrine status. Testosterone therapy helps only the subset with genuine hypogonadism and is not a generic libido drug.
This is something to take to a clinician. The Atlas can tell you what is known about male hypoactive sexual desire disorder in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Male hypoactive sexual desire disorder (HSDD) is persistently or recurrently deficient or absent sexual thoughts, fantasies, and desire for sexual activity, judged in context of age and culture, and, critically, causing marked distress. It is a desire disorder, conceptually separate from erectile dysfunction (an arousal/performance problem) and from situational disinterest. DSM-5 folded prior criteria into this construct. Accurate prevalence is uncertain because most surveys ask about low interest without testing the full duration-and-distress criteria.
Not an erection problem, a desire problem, and a real diagnosis.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Desire is multifactorial: testosterone supports libido, but mood, relationship context, medications (especially SSRIs and prolactin-raising drugs), chronic illness, sleep, and stress all modulate it. Notably, comparative data have found men with HSDD did not differ markedly from men without it in age, serum testosterone, depression scores, or erectile function on average, meaning low testosterone is one possible driver, not a universal explanation.
Safety in detail
Evaluation may include hormonal testing and medication review; testosterone therapy is appropriate only for documented hypogonadism and requires physician evaluation and monitoring given documented health risks of inappropriate use.
What people get wrong
Often saidLow desire in men is always low testosterone
ActuallyAverage testosterone does not reliably separate men with HSDD from those without. Hormones matter for some, but mood, medications, and relationship factors often dominate.
Often saidHSDD and ED are the same thing
ActuallyOne is about wanting sex; the other is about achieving an erection. A man can have either, both, or neither, and the treatments differ.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Hypoactive sexual desire disorder entered formal nosology in DSM-III-R, with DSM-IV adding the requirement of marked distress or interpersonal difficulty. DSM-5 retained a male HSDD diagnosis (while restructuring the female desire/arousal categories). Despite decades in the manuals, male HSDD remains comparatively understudied versus ED.
At a glance
- DSM-5 core
- Deficient/absent sexual thoughts, fantasies, and desire
- Required qualifier
- Marked distress; persistent ~6 months
- Distinct from
- Erectile dysfunction and situational low interest
- Prevalence
- Uncertain, surveys rarely apply full criteria
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Male Hypoactive Sexual Desire Disorder. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Characterization of HSDD in men (Johns Hopkins group)2012
Found no clinically relevant average differences in testosterone, mood, or erectile function between men with and without HSDD, yet HSDD identified a distinct population by desire and distress
DSM diagnostic-criteria analyses2015
Examined how DSM definitions shape who qualifies for the diagnosis and why prevalence figures vary